top of page

Merck and Pfizer's diabetes treatment meets primary endpoint in phase 3 trial

Merck and Pfizer announced that ertugliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor they are developing together, demonstrated significantly greater reductions in glycated hemoglobin (A1C) compared with placebo.

The drug was studied in patients with type 2 diabetes (T2D) in combination with sitagliptin and metformin.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page